Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC20142
- Development stage
- Phase 1
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWC20142 is a small molecule drug developed by Daewoong Pharmaceutical. It has been studied in early-phase clinical trials, primarily to evaluate its pharmacokinetics and potential drug-drug interactions with another investigational compound, DWC20141, in healthy adult subjects. The specific mechanism of action, molecular target(s), and therapeutic indication for DWC20142 have not been publicly disclosed as of the latest available data. There is some association with research into digestive system disorders and gastroesophageal reflux disease (GERD), but no active or approved indications are confirmed[1][2][3].
- Other names
- DWC-20142DWC20142DWC 20142
Beyond the preview
Go deeper on DWC20142.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWC20142.